From the Chair
An expert editorial series from Nephrology Times
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
The benefit-risk ratio and considerations about unmet need are worth considering.
SGLT2i therapy is contraindicated in patients with type 1 diabetes mellitus (T1DM) who have CKD.
The first part of the dialysis moonshot is to prevent the need for dialysis.
Measuring eGFR and UACR is a key component of guideline-directed medical therapy for patients with CKD from type 2 diabetes.
The most important patients who should receive treatment with SGLT2 inhibitors are those with CKD and type 2 diabetes.
Sodium-glucose transport protein 2 (SGLT2) inhibitors (SGLT2i), or gliflozins, block SGLT2 cotransporters in the ...
From the Chair ...
From the Chair ...
Managing blood pressure is probably the most important intervention that a nephrologist pursues in slowing kidney ...
Approximately 221 million people worldwide have been diagnosed with infection from SARS-CoV-2, the virus that causes ...
The approval by the US FDA on August 23, 2021, of difelikefalin (marketed as Korsuva™ by Cara Therapeutics) is a major ...
In a thought-provoking Viewpoint article in JAMA Surgery1, Arthur Matas, MD, makes the case for introducing a regulated ...
Editor's Note:
...
In the July/August 2019 issue of Nephrology Times1 I published an article on the idea of a dialysis moonshot, based on ...
COVID-19 is essentially an acute respiratory illness that in some patients, especially vulnerable groups, can be fatal. ...
In a point-counterpoint-editorial contribution in the January 1 issue of Kidney International, Richard Glassock and ...
Nearly one-half of patients >75 years of age who initiate dialysis are dead within 6 months (almost one-half are dead ...
Advertisement
Advertisement
